Can-Fite BioPharma delays shareholder meeting for quorum

Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders on March 3, 2026, but it was adjourned for one week because there were not enough shareholders present to form a quorum.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. held a Special General Meeting of Shareholders on March 3, 2026, but it was adjourned for one week because there were not enough shareholders present to form a quorum. The Meeting is now scheduled to reconvene on March 10, 2026 at 3:00 p.m., Israel time.

The reconvened Meeting will take place at the Company’s offices at 26 Ben Gurion Street, Ramat Gan, Israel. This update simply informs shareholders of the new date, time and place so they can attend and participate in the Meeting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Can-Fite BioPharma Ltd. (CANF) report in this Form 6-K?

Can-Fite BioPharma Ltd. reported that its Special General Meeting of Shareholders on March 3, 2026 was adjourned. The adjournment occurred because there was not a sufficient quorum, and the Meeting was rescheduled for March 10, 2026 at the same time and place.

Why was Can-Fite BioPharma’s Special General Meeting adjourned?

The Special General Meeting was adjourned due to a lack of quorum, meaning not enough shareholders were present to conduct official business. As a result, the Company postponed the Meeting by one week and announced a new reconvening date and time for shareholders.

When will the Can-Fite BioPharma (CANF) Special General Meeting reconvene?

The Special General Meeting will reconvene on Tuesday, March 10, 2026 at 3:00 p.m., Israel time. The Company kept the same time as the original Meeting while moving it by one week to allow for a sufficient quorum of shareholders to attend.

Where will Can-Fite BioPharma’s reconvened Special General Meeting be held?

The reconvened Special General Meeting will be held at Can-Fite BioPharma’s offices at 26 Ben Gurion Street, Ramat Gan, Israel. This is the same location as the original Meeting, providing continuity and clear guidance for shareholders who plan to attend in person.

What does a lack of quorum mean for Can-Fite BioPharma shareholders?

A lack of quorum means too few shareholders were present to legally conduct the Meeting’s agenda items. For shareholders, it results in a delay, with the Meeting moved to March 10, 2026 so company decisions can be made once enough voting power is represented.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/03/2026 - 04:39 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2026

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 3, 2026, Can-Fite BioPharma Ltd. (the “Company”) convened a Special General Meeting of Shareholders (the “Meeting”). However, the Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Tuesday, March 10, 2026 at 3:00 p.m., Israel time at the Company’s offices located at 26 Ben Gurion Street, Ramat Gan, Israel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 3, 2026	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

Source: View Original Filing on SEC EDGAR